🔗 Share this article

The recently developed medications for gonorrhoea in many years are being described as a "huge turning point" in the battle against superbug strains of the pathogen, according to health experts.

A Global Public Health Issue

Gonorrhoea infections are increasing globally, with figures suggesting more than 82 million new cases each year. Notably increased rates are seen in Africa and countries within the WHO's Western Pacific region, which encompasses China and Mongolia to New Zealand. Across England, cases have hit a all-time high, while figures across Europe in 2023 were three times higher compared to the rates from 2014.

“The clearance of new treatments for gonorrhoea is an important and timely advancement in the face of growing infection rates, the spread of superbugs and the extremely scarce treatment choices currently available.”

Public health authorities are particularly alarmed about the surge in treatment-resistant strains. The global health body has designated it as a "high-priority threat". Recent surveillance found that resistance to standard treatments like cefixime and ceftriaxone had risen sharply between 2022 and 2024.

A Pair of Novel Therapies Receive Approval

Zoliflodacin, alternatively called Nuzolvence, was cleared by the US Food and Drug Administration in recent days for treating gonorrhoea. This disease can lead to major issues, including the inability to conceive. Scientists anticipate that specific application of this new drug will help slow the emergence of superbugs.

Another new antibiotic, originating from the pharmaceutical company GlaxoSmithKline, gained clearance in concurrent days. This treatment, which is employed against UTIs, was proven in research to be effective against antibiotic-resistant forms of the gonorrhoea bacteria.

A Unique Development Model

Zoliflodacin was the result of a innovative non-profit model for antibiotic development. The charitable organization Global Antibiotic Research & Development Partnership worked alongside the pharmaceutical company its industry partner to see it through.

“This milestone signifies a major breakthrough in the management of multidrug-resistant gonorrhoea, which previously has been outpacing antibiotic development.”

Clinical Trial Outcomes and Global Access

According to data detailed in a major medical journal, the new drug successfully treated over nine in ten of cases of the STI. This places it at an equal footing with the typical regimen, which combines an injection and a pill. The trial included hundreds of participants from several countries including the United States, Thailand, South Africa, and European nations.

Under the terms of its unique model, the non-profit has the rights to register and commercialise the drug in many regions with limited resources.

Clinicians on the front lines have voiced hope. The availability of a one-pill regimen like this is described as a "critical tool" for gonorrhoea control. This is considered vital to lessen the impact of the illness for individuals and to stop the proliferation of untreatable gonorrhoea globally.